Cargando…
Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials
This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Neurogastroenterology and Motility
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930296/ https://www.ncbi.nlm.nih.gov/pubmed/27127190 http://dx.doi.org/10.5056/jnm16004 |
_version_ | 1782440732038004736 |
---|---|
author | Sajid, Muhammad S Hebbar, Madhu Baig, Mirza K Li, Andy Philipose, Zinu |
author_facet | Sajid, Muhammad S Hebbar, Madhu Baig, Mirza K Li, Andy Philipose, Zinu |
author_sort | Sajid, Muhammad S |
collection | PubMed |
description | This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18–0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11–0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22–0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to −2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation. |
format | Online Article Text |
id | pubmed-4930296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Society of Neurogastroenterology and Motility |
record_format | MEDLINE/PubMed |
spelling | pubmed-49302962016-07-05 Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials Sajid, Muhammad S Hebbar, Madhu Baig, Mirza K Li, Andy Philipose, Zinu J Neurogastroenterol Motil Meta-Analysis This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18–0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11–0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22–0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to −2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation. Korean Society of Neurogastroenterology and Motility 2016-07 2016-06-28 /pmc/articles/PMC4930296/ /pubmed/27127190 http://dx.doi.org/10.5056/jnm16004 Text en © 2016 The Korean Society of Neurogastroenterology and Motility This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Meta-Analysis Sajid, Muhammad S Hebbar, Madhu Baig, Mirza K Li, Andy Philipose, Zinu Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title | Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title_full | Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title_fullStr | Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title_full_unstemmed | Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title_short | Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials |
title_sort | use of prucalopride for chronic constipation: a systematic review and meta-analysis of published randomized, controlled trials |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930296/ https://www.ncbi.nlm.nih.gov/pubmed/27127190 http://dx.doi.org/10.5056/jnm16004 |
work_keys_str_mv | AT sajidmuhammads useofprucaloprideforchronicconstipationasystematicreviewandmetaanalysisofpublishedrandomizedcontrolledtrials AT hebbarmadhu useofprucaloprideforchronicconstipationasystematicreviewandmetaanalysisofpublishedrandomizedcontrolledtrials AT baigmirzak useofprucaloprideforchronicconstipationasystematicreviewandmetaanalysisofpublishedrandomizedcontrolledtrials AT liandy useofprucaloprideforchronicconstipationasystematicreviewandmetaanalysisofpublishedrandomizedcontrolledtrials AT philiposezinu useofprucaloprideforchronicconstipationasystematicreviewandmetaanalysisofpublishedrandomizedcontrolledtrials |